Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Moderator

James L. Januzzi Jr, MD, FACC, FESC

Hutter Family Professor of Medicine
Division of Cardiology
Massachusetts General Hospital
Faculty
Baim Institute for Clinical Research
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

James L. Januzzi Jr, MD, FACC, FESC, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Beckman Coulter, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Merck; Novartis; Pfizer, Inc.; Roche Diagnostics; Siemens
Research funding from: Abbott; Applied Therapeutics; HeartFlow; Innolife; Roche Diagnostics
Contracted researcher for: Abbott; AbbVie Inc.; CVRx, Inc.; Intercept Pharmaceuticals, Inc.; Takeda

Faculty

Alexandre Mebazaa, MD, PhD

Professor of Medicine
Université Paris Cité
Department of Anaesthesia and Critical Care
University Hospitals Saint Louis‐Lariboisière
Paris, France

Disclosures

Alexandre Mebazaa, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: 4TEEN4 Pharmaceuticals GmbH; Adrenomed; Corteria Pharmaceuticals; Roche Diagnostics; S-Form Pharma
Speaker or member of speakers bureau for: Novartis; Roche Diagnostics; SERVIER
Research funding from: 4TEEN4 Pharmaceuticals GmbH; Abbott Diagnostics; Roche Diagnostics

Stephen J. Greene, MD

Assistant Professor, Division of Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina, United States

Disclosures

Stephen J. Greene, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc./Lilly; Bristol Myers Squibb Company; Corteria Pharmaceuticals; CSL Vifor; Merck; PharmaIN; Roche Diagnostics; Sanofi; scPharmaceuticals; Tricog Health; Urovant Sciences
Speaker or member of speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cytokinetics; Roche Diagnostics
Research funding from: Amgen Inc.; AstraZeneca; Bristol Myers Squibb Company; Cytokinetics; Merck; Novartis; Pfizer, Inc.; Sanofi

Editors

Joy P. Marko, MS, APN-C, CCMEP

Senior Medical Education Director, Medscape, LLC

Disclosures

Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

Frederick Stange, DO

Scientific Content Manager, Medscape, LLC

Disclosures

Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Optimizing Medical Therapy in Acute Heart Failure: Closing the Gap Between Evidence and Implementation

Authors: James L. Januzzi Jr, MD, FACC, FESC; Alexandre Mebazaa, MD, PhD; Stephen J. Greene, MD
CME / ABIM MOC / CE Released: 3/30/2023
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/18/2023

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, diabetologists, endocrinologists, emergency medicine physicians, nurses, pharmacists, and other clinicians involved in the care of patients with acute Heart Failure.

The goal of this activity is for learners to be better able to understand the latest evidence for the rapid uptitration of guideline-directed medical treatment (GDMT) and apply evidence to optimize GDMT in patients with acute heart failure.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest evidence for the rapid uptitration of GDMT during and early after discharge from a HF hospital admission
- Clinical utility of natriuretic peptides in the optimization of GDMT in the acute HF patient population
Have greater competence related to
- Application of the latest evidence for the rapid uptitration of GDMT in appropriate patients with acute HF
Demonstrate greater confidence in their ability to
- Work as part of an interprofessional team to optimize GDMT in patients with acute HF

Disclosures

Disclosures for additional planners can be found here.

Moderator

James L. Januzzi Jr, MD, FACC, FESC

Hutter Family Professor of Medicine
Division of Cardiology
Massachusetts General Hospital
Faculty
Baim Institute for Clinical Research
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

James L. Januzzi Jr, MD, FACC, FESC, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Beckman Coulter, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Merck; Novartis; Pfizer, Inc.; Roche Diagnostics; Siemens
Research funding from: Abbott; Applied Therapeutics; HeartFlow; Innolife; Roche Diagnostics
Contracted researcher for: Abbott; AbbVie Inc.; CVRx, Inc.; Intercept Pharmaceuticals, Inc.; Takeda

Faculty

Alexandre Mebazaa, MD, PhD

Professor of Medicine
Université Paris Cité
Department of Anaesthesia and Critical Care
University Hospitals Saint Louis‐Lariboisière
Paris, France

Disclosures

Alexandre Mebazaa, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: 4TEEN4 Pharmaceuticals GmbH; Adrenomed; Corteria Pharmaceuticals; Roche Diagnostics; S-Form Pharma
Speaker or member of speakers bureau for: Novartis; Roche Diagnostics; SERVIER
Research funding from: 4TEEN4 Pharmaceuticals GmbH; Abbott Diagnostics; Roche Diagnostics

Stephen J. Greene, MD

Assistant Professor, Division of Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina, United States

Disclosures

Stephen J. Greene, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc./Lilly; Bristol Myers Squibb Company; Corteria Pharmaceuticals; CSL Vifor; Merck; PharmaIN; Roche Diagnostics; Sanofi; scPharmaceuticals; Tricog Health; Urovant Sciences
Speaker or member of speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cytokinetics; Roche Diagnostics
Research funding from: Amgen Inc.; AstraZeneca; Bristol Myers Squibb Company; Cytokinetics; Merck; Novartis; Pfizer, Inc.; Sanofi

Editors

Joy P. Marko, MS, APN-C, CCMEP

Senior Medical Education Director, Medscape, LLC

Disclosures

Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

Frederick Stange, DO

Scientific Content Manager, Medscape, LLC

Disclosures

Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-23-027-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Optimizing Medical Therapy in Acute Heart Failure: Closing the Gap Between Evidence and Implementation

Authors: James L. Januzzi Jr, MD, FACC, FESC; Alexandre Mebazaa, MD, PhD; Stephen J. Greene, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 3/30/2023

Valid for credit through: 4/18/2023

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 4

CME / ABIM MOC / CE Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

James L. Januzzi Jr, MD, FACC, FESC

Faculty

Alexandre Mebazaa, MD, PhD

Stephen J. Greene, MD

Editors

Joy P. Marko, MS, APN-C, CCMEP

Frederick Stange, DO

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Optimizing Medical Therapy in Acute Heart Failure: Closing the Gap Between Evidence and Implementation

Target Audience and Goal Statement

Disclosures

Moderator

James L. Januzzi Jr, MD, FACC, FESC

Faculty

Alexandre Mebazaa, MD, PhD

Stephen J. Greene, MD

Editors

Joy P. Marko, MS, APN-C, CCMEP

Frederick Stange, DO

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Optimizing Medical Therapy in Acute Heart Failure: Closing the Gap Between Evidence and Implementation

Learning Feedback Questions